Clinical Trial Detail

NCT ID NCT04152499
Title Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Klus Pharma Inc.
Indications

pancreatic adenocarcinoma

urinary bladder cancer

triple-receptor negative breast cancer

gastric adenocarcinoma

ovary epithelial cancer

Therapies

SKB264

Age Groups: adult senior

No variant requirements are available.